Ariamala Gopalsamy, Lexington, MA (US); Shawn Cabral, Groton, CT (US); Agustin Casimiro-Garcia, Concord, MA (US); Ming Zhu Chen, Mystic, CT (US); Chulho Choi, Mystic, CT (US); Robert Lee Dow, Quincy, MA (US); Olugbeminiyi Omezia Fadeyi, Harvard, MA (US); David Hepworth, Concord, MA (US); Jayasankar Jasti, East Lyme, CT (US); Lyn Howard Jones, Winchester, MA (US); Arjun Venkat Narayanan, Cambridge, MA (US); Mihir Dineshkumar Parikh, East Greenwich, RI (US); David Walter Piotrowski, Waterford, CT (US); Lee Richard Roberts, Belmont, MA (US); Ralph Pelton Robinson, Jr., Gales Ferry, CT (US); and Hatice Gizem Yayla, Mystic, CT (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Apr. 12, 2021, as Appl. No. 17/227,819.
Application 17/227,819 is a continuation of application No. 16/695,709, filed on Nov. 26, 2019, granted, now 11,014,908.
Claims priority of provisional application 62/915,784, filed on Oct. 16, 2019.
Claims priority of provisional application 62/772,815, filed on Nov. 29, 2018.
Prior Publication US 2022/0348555 A1, Nov. 3, 2022
1. A crystal comprising (S)-6-(1-((2-amino-6-fluoroquinolin-3-yl)oxy)ethyl)-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer thereof.